Orthofix Medical Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 9, 2026, reporting third-quarter net sales of $207,862 thousand and a return to operating income of $1,545 thousand.

Key Highlights

  • Net sales of $207,862 thousand for the three months ended September 30, 2026, compared with $205,634 thousand in the same period of 2025, according to the filing.
  • Operating income of $1,545 thousand for Q3 2026, compared with an operating loss of $17,046 thousand in Q3 2025, as reported in the condensed consolidated statements of operations.
  • Nine-month net sales of $615,503 thousand for the nine months ended September 30, 2026, versus $602,401 thousand in the prior-year period, the filing disclosed.
  • Nine-month operating loss of $21,025 thousand, an improvement from the $81,922 thousand operating loss recorded in the nine months ended September 30, 2025.
  • Total assets of $855,761 thousand as of September 30, 2026, up from $850,647 thousand at December 31, 2025, per the balance sheet.
  • Accumulated deficit of $411,113 thousand as of September 30, 2026, compared with $368,333 thousand at December 31, 2025.
  • 40,759,801 shares of common stock issued and outstanding as of November 5, 2026, the filing stated.

Orthofix Medical's Third-Quarter 2026 Financial Position and Results

According to the filing, Orthofix Medical Inc. (NASDAQ:OFIX), headquartered at 3451 Plano Parkway, Lewisville, Texas, reported net sales of $207,862 thousand for the three months ended September 30, 2026, an increase from $205,634 thousand in the comparable prior-year quarter. Gross profit for Q3 2026 was $146,546 thousand, compared with $148,523 thousand in Q3 2025. The company reported sales, general, and administrative expenses of $125,330 thousand for the quarter, down from $148,102 thousand in the same period of 2025.

The filing disclosed operating income of $1,545 thousand for the three months ended September 30, 2026, a shift from the $17,046 thousand operating loss reported in Q3 2025. For the nine-month period, the company reported an operating loss of $21,025 thousand, compared with an operating loss of $81,922 thousand for the nine months ended September 30, 2025. Research and development expense for the nine months was $46,541 thousand, versus $50,474 thousand in the prior-year nine-month period. Net interest expense was $5,889 thousand for Q3 2026, compared with $4,681 thousand in Q3 2025.

As of September 30, 2026, total assets were $855,761 thousand, with cash and cash equivalents of $86,322 thousand, up from $82,025 thousand at December 31, 2025. Long-term debt rose to $221,847 thousand from $157,391 thousand at year-end 2025. Total shareholders' equity stood at $429,567 thousand, down from $450,037 thousand at December 31, 2025, reflecting the widened accumulated deficit. The filing noted that 40,749 thousand shares were issued and outstanding as of September 30, 2026, with the common shares carrying a $0.10 par value and 100,000 thousand shares authorized. The company classified itself as an accelerated filer for the reporting period.

What Was Disclosed

Orthofix Medical filed its quarterly report covering the period ended September 30, 2026, disclosing Q3 net sales, a return to operating income for the quarter, year-to-date financial results, balance sheet data including increased long-term debt, and share count as of November 5, 2026.